We are live on ! Find out more
CRSP icon

CRISPR Therapeutics
CRSP

253 hedge funds and large institutions have $1.92B invested in CRISPR Therapeutics in 2019 Q4 according to their latest regulatory filings, with 91 funds opening new positions, 68 increasing their positions, 52 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

406% more first-time investments, than exits

New positions opened: 91 | Existing positions closed: 18

70% more capital invested

Capital invested by funds: $1.13B → $1.92B (+$791M)

39% more funds holding

Funds holding: 182 → 253 (+71)

31% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 52

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

2.91% more ownership

Funds ownership: 50.39% → 53.3% (+2.9%)

4% less call options, than puts

Call options by funds: $55.6M | Put options by funds: $58.2M

Holders
253
Holders Change
+71
Holders Change %
+39.01%
% of All Funds
4.99%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.12%
New
91
Increased
68
Reduced
52
Closed
18
Calls
$55.6M
Puts
$58.2M
Net Calls
-$2.58M
Net Calls Change
-$3.6M

Top Buyers

1
Ameriprise
Ameriprise
Minnesota
+$24.5M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$22.5M
3
Federated Hermes
Federated Hermes
Pennsylvania
+$21.8M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$21.7M
5
Two Sigma Investments
Two Sigma Investments
New York
+$19.8M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$15.3M
2
OTPPB
Ontario Teachers' Pension Plan Board
Ontario, Canada
-$13.2M
3
FCM
Farallon Capital Management
California
-$11.5M
4
AC
Armistice Capital
New York
-$6.33M
5
Wells Fargo
Wells Fargo
California
-$6.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
26
Two Sigma Advisers
New York
$17.5M +$12.6M +230,400 +402%
Lord, Abbett & Co
27
Lord, Abbett & Co
New Jersey
$17.2M -$4.07M -74,587 -21%
VCM
28
Valiant Capital Management
California
$16.5M – – –
Morgan Stanley
29
Morgan Stanley
New York
$15.5M -$190K -3,477 -1%
JP Morgan Chase
30
JP Morgan Chase
New York
$14.5M +$12.8M +234,025 +5,083%
Citadel Advisors
31
Citadel Advisors
Florida
$12.6M +$11.3M +207,258 New
Susquehanna International Group
32
Susquehanna International Group
Pennsylvania
$12M +$4.13M +75,631 +62%
Vanguard Group
33
Vanguard Group
Pennsylvania
$10.4M +$4.81M +88,044 +107%
AC
34
Armistice Capital
New York
$9.01M -$6.33M -116,000 -44%
Deutsche Bank
35
Deutsche Bank
Germany
$8.17M +$5.31M +97,244 +264%
Invesco
36
Invesco
Georgia
$8.12M +$5.67M +103,822 +351%
Goldman Sachs
37
Goldman Sachs
New York
$7.92M +$4.04M +73,934 +132%
CAI
38
Capital Advisors Inc
Oklahoma
$7.74M +$594K +10,872 +9%
Royal Bank of Canada
39
Royal Bank of Canada
Ontario, Canada
$6.59M +$120K +2,206 +2%
Arrowstreet Capital
40
Arrowstreet Capital
Massachusetts
$6.32M +$5.67M +103,800 New
LCM
41
Laurion Capital Management
New York
$6.09M +$5.46M +100,000 New
CCI
42
Columbus Circle Investors
$6.02M +$5.4M +98,888 New
EIM
43
Essex Investment Management
Massachusetts
$5.08M +$253K +4,629 +6%
PP
44
Peconic Partners
New York
$4.84M -$3.28M -60,000 -43%
SC
45
Sculptor Capital
New York
$4.67M – – –
FCM
46
Frontier Capital Management
Massachusetts
$4.67M +$4.18M +76,636 New
TCM
47
Tekla Capital Management
Massachusetts
$4.64M -$1.37M -25,114 -25%
William Blair & Company
48
William Blair & Company
Illinois
$4.3M +$597K +10,928 +18%
Voloridge Investment Management
49
Voloridge Investment Management
Florida
$3.63M +$3.26M +59,617 New
HAM
50
HHR Asset Management
New Jersey
$3.57M -$320K -5,860 -9%
1
2
3 4 5

CRSP Hedge Fund Activity: Q4 2019 in Review

253 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q4 2019, worth a combined $1.92B — up 70% from $1.13B a quarter earlier.

Buyers outnumbered sellers: 91 funds opened new CRSP positions and 18 closed out — a net gain of 73 holders — while 68 added to existing stakes and 52 trimmed.

The largest buyer was Ameriprise, adding an estimated $24.5M. The largest seller was Wellington Management Group, cutting an estimated $15.3M.

  • 253 institutional investors held CRISPR Therapeutics (CRSP) as of Q4 2019, up from 182 in Q3 2019.
  • Funds reported $1.92B of CRISPR Therapeutics stock for Q4 2019, up 70% quarter-over-quarter.
  • 91 funds opened new CRISPR Therapeutics positions in Q4 2019 and 18 closed out, a net change of +73 holders.
  • The largest CRISPR Therapeutics buyer in Q4 2019 was Ameriprise, an estimated $24.5M added.
  • The largest CRISPR Therapeutics seller in Q4 2019 was Wellington Management Group, an estimated $15.3M sold.

Based on aggregated 13F filings for Q4 2019.